Shares of Zydus Lifesciences Limited garnered attention this morning after a High Court ruling authorized the company to produce semaglutide for export to specific nations. The stock saw movement, reflecting investor response to the news.
Zydus Lifesciences Limited's shares were closely watched in morning trading following a High Court order that permits the company to produce semaglutide for export to certain countries. At 11:29 AM, the shares showed a 0.66% increase, trading at Rs 924.30.
Trading activity saw the stock fluctuate within a tight band early on. Shares moved between a daily low of ₹915.45 and a high of ₹926.00 by 11:27 AM, compared to the previous day's closing price of ₹918.20.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
The stock's 52-week range has been between ₹795.00 and ₹1,059.05. The volume of shares traded during the session was 1,03,689.
Original source: Business Upturn
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.
Urban India faces a metabolic crisis with 73 million overweight adults, yet GLP-1 therapy awareness hovers below 5%, per Kantar's latest report. Despite high weight loss intent, a stark knowledge gap limits adoption of these diabetes and obesity treatments. Explore the data, demographics, and paths forward for better metabolic health.
